Article
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
The Korean journal of internal medicine - 1 Jul 2019
Oh Jae Young, Kim Byung Seok, Lee Chang Hyeong, Song Jeong Eun, Lee Heon Ju, Park Jung Gil, Hwang Jae Seok, Chung Woo Jin, Jang Byoung Kuk, Kweon Young Oh, Tak Won Young, Park Soo Young, Jang Se Young, Suh Jeong Ill, Kwak Sang Gyu
Abstract excerpt
BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients with chronic hepatitis C virus (HCV) genotype 1b infection in real world. METHODS: We enrolled 278 patients (184...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.